Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin

Biochem Biophys Res Commun. 2019 Sep 24;517(3):538-544. doi: 10.1016/j.bbrc.2019.07.046. Epub 2019 Jul 31.

Abstract

Doxorubicin (DOX) is an antitumor drug widely used in hematological tumors and various solid tumors. However, the cardiotoxicity elicited by DOX severely limits its clinical treatment. Dimethyl itaconate (DI), a common form of itaconate, is found many potential targets for prevent heart injury. Here we employed wild type and Nrf2 knockout mice and induced a cardiotoxicity model by administration of DOX to clarify the effects of DI. After treatment with DI, we found that it could effectively alleviate the cardiotoxicity by analyzing morphology, LDH levels and heart weight/body weight ratio changes. Meanwhile we demonstrated that RIP3, a key protein of necrosis, was significantly decreased in DI treated group. Further we observed that treatment with DI could suppress oxidative stress by altering Nrf2/HO-1. Compared with vehicle group, DI could increase the tissue SOD and GSH, and reduce MDA levels, then DHE staining revealed that the level of ROS in DI group reduced by half. Finally, transmission electron microscope (TEM) data showed that treatment with DI obviously decreased the mitochondrial damage. While Nrf2 was ablated in mice, the protective effects of DI were vanished and SOD, GSH, MDA became unchanged related to vehicle group. This report provides the evidence for the protective effects of DI treatment in cardiotoxicity induced by DOX. On mechanisms, DI could reduce the oxidative stress by altering Nrf2/HO-1 pathway and prevent mitochondrial from damage. Taken together, these findings of this paper will afford the new therapeutic targets in DOX related cardiotoxicity.

Keywords: Acute cardiotoxicity; Dimethyl itaconate; Doxorubicin; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Antibiotics, Antineoplastic / adverse effects
  • Cardiotonic Agents / pharmacology*
  • Cardiotoxicity / etiology
  • Cardiotoxicity / genetics
  • Cardiotoxicity / pathology
  • Cardiotoxicity / prevention & control*
  • Doxorubicin / adverse effects
  • Doxorubicin / antagonists & inhibitors*
  • Gene Expression
  • Glutathione / metabolism
  • Heme Oxygenase-1 / genetics
  • Heme Oxygenase-1 / metabolism
  • Male
  • Malondialdehyde / antagonists & inhibitors
  • Malondialdehyde / metabolism
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • Myocardium / metabolism
  • Myocardium / pathology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • NF-E2-Related Factor 2 / deficiency
  • NF-E2-Related Factor 2 / genetics*
  • Oxidative Stress / drug effects
  • Reactive Oxygen Species / antagonists & inhibitors
  • Reactive Oxygen Species / metabolism
  • Receptor-Interacting Protein Serine-Threonine Kinases / genetics
  • Receptor-Interacting Protein Serine-Threonine Kinases / metabolism
  • Succinates / pharmacology*
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / metabolism

Substances

  • Antibiotics, Antineoplastic
  • Cardiotonic Agents
  • Membrane Proteins
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • Reactive Oxygen Species
  • Succinates
  • dimethyl itaconate
  • Malondialdehyde
  • Doxorubicin
  • Heme Oxygenase-1
  • Hmox1 protein, mouse
  • Superoxide Dismutase
  • Receptor-Interacting Protein Serine-Threonine Kinases
  • Ripk3 protein, mouse
  • Glutathione